STAAR Surgical (STAA) faces Q1 earnings test as analysts cut revenue estimates

STAAR Surgical (STAA) is scheduled to report first-quarter results after the market close on May 15, 2026, with analysts expecting revenue to rise 81.8% from a year earlier, reversing a 44.9% decline in the prior-year quarter. The medical lens maker reported $57.8 million in revenue last quarter, up 18.1% year over year, but missed Wall Street estimates for both revenue and earnings per share. Analysts have reduced most revenue forecasts over the past 30 days, and the company has missed consensus revenue estimates several times in the past two years. Recent peer results were mixed for investors. Globus Medical posted 27% revenue growth, beating estimates by 2.7%, but its shares fell 8.4%. Haemonetics revenue rose 4.8%, topping estimates by 2.6%, and its shares gained 4.7%. STAAR shares are up 3.4% over the past month, compared with a 2.3% average gain for specialty medical device peers, and trade at $27.74 versus an average analyst target of $21.11.